A 17-year-old Aboriginal girl from a remote community is diagnosed with definite rheumatic heart disease involving the mitral valve following prior episodes of acute rheumatic fever. According to Australian ARF/RHD guidelines, what is the recommended duration of secondary benzathine benzylpenicillin prophylaxis in high-risk settings such as hers, assuming no contraindications and ongoing risk?